P

harma has had a rocky relationship with President Trump since inauguration, but the two agree on at least one thing: Corporate taxes are too high.

And yet the nation’s biggest drug makers aren’t paying anywhere near the top corporate tax rate Trump, and congressional Republicans, hope to slash.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Is the “government” misleading America or do our “elected” well paid “leaders” think that we are all totally ignorant ?????
    I, for one, am appalled that our “President” really believes his Tax Amendment Bill is actually helpful to Americans ???
    His proposed Tax Reform Bill doesn’t even deserve the time of Congress to review.
    Just heave it the trash bucket !!!!!!

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy